

EXHIBIT B



REUTERS

EDITION: IN

[Register](#) | [Sign In](#)

[Search News & Quotes](#)



[Home](#)

[Business](#)

[Markets](#)

[India](#)

[World](#)

[Tech](#)

[Opinion](#)

[Breakingviews](#)

[Money](#)

[Sport & Life](#)

[Pictures](#)

[Video](#)

EDITION: IN

Lupin Ltd (LUPN.NS)

Related Topics: [STOCK QUOTES](#) [HEALTHCARE](#) [PHARMACEUTICALS - GENERIC / SPECIALTY](#)

[OVERVIEW](#)

[NEWS](#)

[KEY DEVELOPMENTS](#)

[PEOPLE](#)

[CHARTS](#)

[FINANCIALS](#)

[OPTIONS](#)

[ANALYSTS](#)

LUPN.NS on National Stock
Exchange of India

Price Change (% chg)

Prev Close
Rs434.80

Day's High
Rs433.50

Volume
1,383,432

52-wk High
Rs494.00

426.45INR
13 Dec 2011

Rs-8.35 (-1.92%)

Open
Rs433.25

Day's Low
Rs423.35

Avg. Vol
644,075

52-wk Low
Rs363.10


[Login](#) or [register](#)

Latest from
My Wire

1

Recent
Companies


LUPN.NS



ABOUT

Lupin Limited is an India-based pharmaceutical company. The company produces a range of generic and branded formulations and Active Pharmaceutical Ingredients (APIs). The Company's product basket consists of formulations from Cephalosporins, CVS, CNS, Anti-Asthma, Anti-TB, Diabetology, Dermatology, GI, and other therapy... (more)

BUY/SELL



Must Watch Videos

by Taboola

OVERALL

Beta:

0.45

Market Cap (Mil.):

Rs194,175.80

Shares Outstanding (Mil.):

446.59

Dividend:

3.00

Yield (%):

0.69

FINANCIALS

P/E (TTM):

LUPN.NS

Industry

Sector

21.01

19.21

21.02

EPS (TTM):

17.00

--

--

ROI:

19.40

9.95

8.95

ROE:

27.32

11.80

11.14

SEARCH STOCKS

Enter company name or Symbol

SEARCH

LATEST NEWS ABOUT LUPN.NS

MARKET EYE-Lupin down after US court stays import, sale of Fortamet

Shares of Lupin fell after Shionogi Pharma Inc said a the district court in New Jersey moved a preliminary injunction against the Indian company to stop importing and selling any the generic version of Type 2 diabetes treatment Fortamet in the United States, two institutional salemen said. Fortamet is a subject of a patent infringement suit between the firms, but the US court denied patent holder Shionogi Pharma Inc's request to recall the generics already in the market. The preliminary injunctio

08 Dec 2011

UPDATE 1-Lupin gets U.S. nod for oral antibiotic, shares up

MUMBAI, Dec 2 - Indian drugmaker Lupin will sell the generic version of oral antibiotic Solodyn in the U.S. after it received regulatory nod for the \$750-million-a-year drug, it said on Friday.

02 Dec 2011

MARKETEYE-Lupin shares rise on U.S. nod for oral contraceptive

Shares in drugmaker Lupin rose nearly 2 percent after it received U.S. regulatory approval on Tuesday to launch oral contraceptive tablets norethindrone, two dealers said. The tablets are generic version of Watson Pharmaceuticals' brand Nor-QD and have annual sales of about \$52 million in the U.S. This is Lupin's first approval from 26 filings made in the oral contraceptives segment, which has market size of over \$4.5 billion in the U.S. At 10:17 a.m., the stock was up 0.78 percent at 487.25 ru

21 Sep 2011

UPDATE 1-Lupin gets US nod for its 1st oral contraceptive

MUMBAI, Sept 20 - Indian drugmaker Lupin said on Tuesday it has received the U.S. Food and Drug Administration's approval to sell its first oral contraceptive, norethindrone tablets, in the country.

20 Sep 2011

UPDATE 1-Lupin unit, Sanofi-Aventis Philippines in marketing pact

MUMBAI, Sept 2 - Sanofi-Aventis Philippines, part of Sanofi group , has signed an agreement with a unit of India's

Canada cracks down on veils

Reuters India provides top breaking news videos, live news videos online. Reuters is your online source to...

Iran slams
U.S. over

Weaker
economic

Deadly
explosions r...

Precious Metal Investing

Build and Preserve Wealth with
Blanchard Precious Metal Investing.
BlanchardOnline.com

AdChoices

EARNINGS VS ESTIMATES

Last Five Estimates

Q2	5.95	▼
Q1	4.69	▼
Q4	5.07	▼
Q3	5	▼
Q2	4.8	▼

Future Estimates

Q2 11	5.728
Q1 12	5.77

Login or register

Latest from
My Wire

Recent
Companies

Related Topics: STOCK QUOTES HEALTHCARE PHARMACEUTICALS - GENERIC / SPECIALTY

SEARCH STOCKS

Enter company name or Symbol

SEARCH

Back to top

Reuters.com

Business | Markets | India | Technology | Opinion | Money | Pictures | Videos | Site Index | Mobile

Legal

Bankruptcy Law | California Legal | New York Legal | Securities Law

Support & Contact

Contact Us | Advertise With Us

Account Information

Register | Sign In

Connect with Reuters

Twitter | Facebook | LinkedIn | RSS | Newsletters

About

Privacy Policy | Terms of Use

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.

Thomsonreuters.com

About Thomson Reuters

Investor Relations

Careers

Contact Us

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Login or register

Latest from My Wire

1 Recent Companies